A comprehensive meta-analysis of the POTOMAC, CREST, and ALBAN trials reveals that adding PD-(L)1 inhibitors to BCG improves event-free survival in high-risk NMIBC. However, increased toxicity and agent-specific variations in efficacy suggest a need for cautious, individualized clinical adoption.